Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) fell 6.1% during trading on Monday . The company traded as low as $18.60 and last traded at $18.62. 1,082 shares traded hands during trading, a decline of 84% from the average session volume of 6,760 shares. The stock had previously closed at $19.84.
Calliditas Therapeutics AB (publ) Stock Performance
The firm has a market capitalization of $554.69 million, a P/E ratio of -7.72 and a beta of 1.46. The stock has a 50-day moving average of $18.44 and a 200 day moving average of $17.12. The company has a debt-to-equity ratio of 0.64, a quick ratio of 4.42 and a current ratio of 4.42.
Get
Calliditas Therapeutics AB (publ) alerts:
Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.03) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.81. The firm had revenue of $24.69 million for the quarter, compared to analyst estimates of $11.52 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 76.33% and a negative net margin of 168.20%. On average, research analysts anticipate that Calliditas Therapeutics AB will post -2.1 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in shares of Calliditas Therapeutics AB (publ) in the 1st quarter worth $221,000. Tower Research Capital LLC TRC boosted its position in shares of Calliditas Therapeutics AB (publ) by 1,270.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company's stock worth $51,000 after purchasing an additional 3,112 shares during the last quarter. HBK Sorce Advisory LLC bought a new position in shares of Calliditas Therapeutics AB (publ) in the 3rd quarter worth $50,000. Finally, Optiver Holding B.V. boosted its position in shares of Calliditas Therapeutics AB (publ) by 1,304.3% in the 3rd quarter. Optiver Holding B.V. now owns 12,625 shares of the company's stock worth $191,000 after purchasing an additional 11,726 shares during the last quarter. 3.13% of the stock is currently owned by institutional investors.
Calliditas Therapeutics AB (publ) Company Profile
(Get Rating)
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.
Read More
- Get a free copy of the StockNews.com research report on Calliditas Therapeutics AB (publ) (CALT)
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
- GE Healthcare Technology: Speculating On Dividends
Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.
